Mesenchymal stem cell therapy promotes the improvement and recovery of renal function in a preclinical model

Genetics and Molecular Biology

Volumn 39, Issue 2, 2016, Pages 290-299

  Urt Filho, Antônio ^a,b   Oliveira, Rodrigo Juliano ^a,b   Hermeto, Larissa Correa ^c   Pesarini, João Renato ^a,b   de David, Natan ^a,b   Cantero, Wilson de Barros ^a,b   Falcão, Gustavo ^b   Marks, Guido ^b   Antoniolli Silva, Andréia Conceição Milan Brochado ^a,b  

^a Brazilian Hospital Services Company EBSERH   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bone marrow; Chemotherapy; Kidney disease; Nephrotoxicity; Tissue regeneration

Indexed keywords

CREATININE; UREA;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXTRACELLULAR MATRIX; KIDNEY FUNCTION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; RAT; UREA BLOOD LEVEL;

EID: 84974801099     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/1678-4685-GMB-2015-0178     Document Type: Article

References (71)

1. Angeli JP, Ribeiro LR, Gonzaga ML, Soares S de A, Ricardo MP, Tsuboy MS, Stidl R, Knasmueller S, Linhares RS and Mantovani MS (2006) Protective effects of beta-glucan extracted from Agaricus blazei against chemically inducedDNAdamage in human lymphocytes. Cell Biol Toxicol 22:285-291.
2. Angeli JP, Ribeiro LR, Angeli JL and Mantovani MS (2009a) Protective effects of beta-glucan from barley against benzo[ a]pyrene-induced DNA damage in hepatic cell HepG2. Exp Toxicol Pathol 61:83-89.
3. Angeli JP, Ribeiro LR, Bellini MF and Mantovani MS (2009b) Beta-glucan extracted from the medicinal mushroom Agaricus blazei prevents the genotoxics effects of benzo[ a]pyrene in the human hepatoma cel line HepG2. Arch Toxicol 83:81-86.
4. Best TM, Fiebig R, Corr DT, Brickson S and Ji L (1999) Free radical activity, antioxidant enzyme, and glutathione changes with muscle stretch injury in rabbits. J Appl Physiol 87:74-82.
5. Brickson S, Hollander J, Corr DT, Ji LL and Best TM (2001) Oxidant production and immune response after stretch injury in skeletal muscle. Med Sci Sports Exerc 33:2010-2015.
6. Brodie JC and Humes HD (2005) Stem cell approaches for the treatment of renal failure. Pharmacol Rev 57:299-313.
7. Butterfield TA, Best TM and Merrick MA (2006) The dual roles of neutrophils and macrophages in inflammation: A critical balance between tissue damage and repair. J Athl Train 41:457-465.
8. Camargo JLV, Oliveira MLCS, Rocha NS and Ito N (1994) A detecção de substâncias cancerígenas em estudos experimentais. Rev Bras Cancerol 40:21-30.
9. Choi SJ, Kim JK and Hwang SD (2010) Mesenchymal stem cell therapy for chronic renal failure. Expert Opin Biol Ther 10:1217:1226.
10. Chorvatovicová D (1991) Suppressing effects of glucan on micromuceli induced by Co60 in mice. Strahlenther Onkol 167:612-614.
11. Chorvatovicová D, Machová E and Sandula J (1996) Effect of ultrasonicated carboxymethilglucan on cyclophosphamide induced mutagenicity. Mutat Res 371:115-120.
12. Chorvatovicová D, Machová E and Sandula J (1998) Ultrasonication: The way to achieve antimutagenic effect of carboxymethyl- chitin-glucan by oral administration. Mutat Res 412:83-89.
13. Cisneros RL, Gibson FC and Tzianabos AO (1996) Passive transfer of poly-(1-6)- β- glucotriosyl-(1-3)- β -glucopyranose glucana protection against lethal infection in an animal model of intra-abdominal sepsis. Infect Immun 64:2201-2205.
14. Cline SD and Hanawalt PC (2003) Who’s on first in the cellular response to DNA damage? Nat Rev Mol Cell Biol 4:361-372.
15. De Flora S (1998) Mechanisms of inhibitors of mutagenesis and carcinogenesis. Mutat Res 402:151-158.
16. Demir G, Klein HO, Mandel-Molinas N and Tuzuner N (2007) β -glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7:113-116.
17. Di Luzio NR, Williams DL, Mcnamee RB, Edwards BF and Kitahama A (1979) Comparative tumor-inhibitory and antibacterial activity of soluble and particulate glucan. Int J Cancer 24:773-779.
18. Dragsted LO, Strube M and Larsen JC (1993) Cancer-protective factors in fruits and vegetables: Biochemical and biological background. Pharmacol Toxicol 72:116-135.
19. Dusse LMS, Vieira LM and Carvalho MG (2003) Nitric oxide revision. J Bras Patol Med Lab 39:343-350.
20. Erpicum P, Detry O, Weekers L, Bonvoisin C, Lechanteur C, Briquet A, Beguin Y, Krzesinski JM and Jouret F (2014) Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrol Dial Transplant 29:1487-1493.
21. Fearon ER and Jones PA (1992) Progressing toward a molecular description of colorectal cancer development. FASEB J 6:2783-2790.
22. Fry AC and Farrington K (2006) Management of acute renal failure. Postgrad Med J 82:106-116.
23. Gordon JA and Gattone 2nd VH (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991-F998.
24. Grimm PC, Nickerson P, Jeffery J, Savani RC, Gough J, McKenna RM, Stern E and Rush DN (2001) Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 345:93-97.
25. Hayashi M, Morita T, Kodama Y, Sofuni T and Ishidate Jr M (1990) The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides. Mutat Res 245:245-249.
26. Hermeto LC, Oliveira RJ, Matuo R, Jardim PH, DeRossi R, Antoniolli AC, Deffune E, Evaristo TC and Santana ÁE (2015) Evaluation of pH effects on genomic integrity in adipose- derived mesenchymal stem cells using the comet assay. Genet Mol Res 14:339-348.
27. Hoste EA and Schurgers M (2008) Epidemiology of acute kidney injury: How big is the problem? Crit Care Med 36:S146- S151.
28. Humphreys BD, Soiffer RJ and Magee CC (2005) Renal failure associated with cancer and its treatment: An update. J Am Soc Nephrol 16:151-161.
29. Kada T, Inoue T and Namiki N (1982) Environmental desmutagens and antidesmutagens. In: Klekowski EJ (ed) Environmental Mutagenesis and Plant Biology. Praeger, New York, pp 137-151.
30. Kada T and Shimoi K (1987) Desmutagens and bio-antimutagens: Their modes of action. BioEssays 7:113-115.
31. Kaneno Y, Chihara G and Taguchi T (1989) Activity of lentinan against cancer and AIDS. Int J Immunother 4:203-213.
32. Kobayashi H, Sugiyama C, Morikawa Y, HayashiMand Sofuni T (1995) A comparison between manual microscopic analysis and computerized image analysis in the single cell gel electrophoresis assay. MMS Communications 2:103-115.
33. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
34. Kumar V, Sinha AK, Makkar HP, de Boeck G and Becker K (2012) Dietary roles of non-starch polysachharides in human nutrition: A review. Crit Rev Food Sci Nutr 52:899-935.
35. Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR and Westenfelder C (2005) Administered mesenchymal stem cells enhance recovery from ischemia/reperfusioninduced acute renal failure in rats. Kidney Int 68:1613-1617.
36. Lazarová M, Lábaj J, Kogan G and Slamenová D (2006) Carboxymethyl chitin-glucan enriched diet exhibits protective effects against oxidative DNA damage induced in freshly isolated rat cells. Neoplasma 53:434-439.
37. Lin H, She Y, Cassileth B, Sirotnak F and Rundles SC (2004) Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int. Immunopharmacology 4:91-99.
38. Luiking YC, Poeze M, Ramsay G and Deutz NE (2005) The role of arginine in infection and sepsis. J Parenter Enteral Nutr 29:70-74.
39. Magnani M, Castro-Gomez RJH, Mori MP, Kyasne H, Gregório EP, Libos-Jr F and Cólus IMS (2011) Protective effect of carboxymethyl-glucan (CM-G) against DNA damage in patients with advanced prostate cancer. Genet Mol Biol 34:131-135.
40. Manoharan K and Banerjee MR (1985) beta-Carotene reduces sister chromatid exchanges induced by chemical carcinogens in mouse mammary cells in organ culture. Cell Biol Int Rep 9:783-789.
41. Mantovani MS, Bellini MF, Angelia JPF, Oliveira RJ, Silva AF and Ribeiro LR (2008) β-Glucans in promoting health: Prevention against mutation and cancer. Mutat Res 658:154-161.
42. Masihi KN (2000) Immunomodulators in infectious diseases panoply of possibilities. Int J Immunopharmacol 22:1083-1091.
43. McCord JM (1993) Human disease, free radicals, and the oxidant/ antioxidant balance. Clin Biochem 26:351-357.
44. Oliveira RJ, Ribeiro LR, Silva AF, Matuo R and Mantovani MS (2006) Evaluation of antimutagenic activity and mechanisms o action of beta-glucan from barley, in CHO-k1 and HTC cell lines using the micronucleus test. Tox in Vitro 20:1225-1233.
45. Oliveira RJ, Matuo R, Silva AF, Matiazi HJ, Mantovani M and Ribeiro LR (2007) Protective effect of beta-glucan extracted from Saccharomyces cerevisiae, against DNA damage and cytotoxicity in wild-type (k1) and repair-deficient (xrs5) CHO cells. Tox in Vitro 21:41-52.
46. Oliveira RJ, Salles MJ, da Silva AF, Kanno TYN, Lourenço ACS, Freiria GA, Matiazi HJ, Ribeiro LR and Mantovani MS (2009a) Effects of the polysaccharide β -glucan on clastogenicity and teratogenicity caused by acute exposure to cyclophosphamide in mice. Regul Toxicol Pharmacol 53:164-173.
47. Oliveira RJ, Baise E, Mauro MO, Pesarini JR, Matuo R, Silva AF, Ribeiro LR and Mantovani MS (2009b) Evaluation of chemopreventive activity of glutamine by the comet and the micronucleus assay in mice’s peripheral blood. Environ Toxicol Pharmacol 28:120-124.
48. Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA and Verhaar MC (2015) Cell-based therapies for experimental chronic kidney disease: A systematic review and meta-analysis. Dis Model Mech 8:281-293.
49. Patchen ML, D’Alesandro MM, Brook I, Blakely WF and Mac Vittie TJ (1987) Glucan: Mechanisms involved in its radioprotective effect. J Leukocyte Biol 42:95-105.
50. Pinkerton pH and Dubé ID (1991) Chronic myeloid leukemia as a paradigm for oncogenesis. Diagnon Oncol 1:288-297.
51. Pitot HC (1993) The molecular biology of carcinogenesis. Cancer 72:962-970.
52. Pitot HC and Dragan Y (1991) Facts and theories concerning the mechanisms of carcinogenesis. FASEB J 5:2280-2286.
53. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, et al. (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713-723.
54. Ren L, Zhou Q, Hou M, Qiu M, He J and Chen H (2002) Monitoring of the renal function changes during chemotherapy based on high-dose cisplatin in patients with lung cancer. Zhongguo Fei Ai Za Zhi 5:363-365.
55. Salvadori DMF, Ribeiro LR and Fenech M (2003) Teste do micronúcleo em células humanas in vitro. In: Ribeiro LR, Salvadori DMF and Marques EK (eds) Mutagênese Ambiental. ULBRA, Canoas, pp 201-219.
56. Serpeloni JM, Batista BL, Angeli JP, Barcelos GR, Bianchi M de L, Barbosa Jr F and Antunes LM (2013) Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo. J Toxicol Environ Health A 76:345-353.
57. Silva AF, Oliveira RJ, Niwa AM, D’Epiro GFR, Ribeiro LR and Mantovani MS (2012) Anticlastogenic effect of β -glucan, extracted from Saccharomyces cerevisiae, on cultured cells exposed to ultraviolet radiation. Cytotechnology 65:41-48.
58. Singh NP, McCoy MT, Tice RR and Schneider EL (1988) A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
59. Slamenová D, Lábaj J, Krizková L, Kogan G, Sandula J, Bresgen N and Eckl P (2003) Protective effects of fungal (1 →3)– β-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cells. Cancer Lett 198:153-160.
60. Sugimura T (1992) Multistep carcinogenesis: A 1992 perspective. Science 258:603-607.
61. Tögel F, Isaac J, Hu Z, Weiss K and Westenfelder C (2005) Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289:F31-F42.
62. Tohamy AA, El-Ghor AA, El-Nahas SM and Noshy MM (2003) β-Glucan inhibits the genotoxicity of cyclophosphamide, adramycin and cisplatin. Mutat Res 541:45-53.
63. Torrinhas RSMM, Campos LDN and Mazza RPJ (2006) Metodologia na pesquisa de dieta, nutrição e câncer: Estudos experimentais em modelos animais e culturas de células. In: Waitzberg DL (ed) Dieta, Nutrição e Câncer. Ateneu, São Paulo, pp 665-674.
64. Turnbull JL, Patchen ML and Scadden DT (1999) The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol 102:66-71.
65. Vieira MH, Oliveira RJ, Eça LP, Pereira IS, Hermeto LC, Matuo R, Fernandes WS, Silva RA and Antoniolli AC (2014) Therapeutic potential of mesenchymal stem cells to treat Achilles tendon injuries. Genet Mol Res 13:10434-10449.
66. Xiao Z, Trincado CA and Murtaugh MP (2004) β-Glucan enhancement of T cell IFN-gamma response in swine. Vet Immunol Immunopathol 102:315-320.
67. Waters MD, Brady AL, Stack HF and Brockman HE (1990) Antimutagenicity profiles for some model compounds. Mutat Res 238:57-85.
68. Wen X, Murugan R, Peng Z and Kellum JA (2010) Pathophysiology of acute kidney injury: A new perspective. Contrib Nephrol 165:39-45.
69. Yokoo T, Sakurai K, Ohashi T and Kawamura T (2003) Stem cell gene therapy for chronic renal failure. Curr Gene Ther 3:387-394.
70. Zerbini G, Piemonti L, Maestroni A, Dell’Antonio G and Bianchi G (2006) Stem cells and the kidney: A new therapeutic tool? J Am Soc Nephrol 17:S123-S126.
71. Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT and DeMong DE (1998) A novel carbohydrate-glycosphingolipid interaction between a β-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem 273:22014-22020.